Comparative Pharmacology
Head-to-head clinical analysis: NATAZIA versus TAYTULLA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NATAZIA versus TAYTULLA.
NATAZIA vs TAYTULLA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estetrol is a selective estrogen receptor modulator (SERM) with mixed agonist/antagonist activity; drospirenone is a spironolactone analog with antimineralocorticoid and antiandrogenic activity. Combined oral contraceptive inhibits ovulation and alters cervical mucus.
Combination of drospirenone, a spironolactone analog with antimineralocorticoid and antiandrogenic activity, and ethinyl estradiol, an estrogen. Suppresses gonadotropins, primarily luteinizing hormone, inhibiting ovulation. Increases cervical mucus viscosity and alters endometrial receptivity.
Drospirenone 3 mg / ethinyl estradiol 0.03 mg orally once daily for 21 days followed by 7 days of placebo.
One capsule orally once daily for 24 weeks.
None Documented
None Documented
Terminal half-life approximately 30 hours for drospirenone and 24 hours for ethinyl estradiol; steady-state achieved within 8–10 days.
Terminal elimination half-life: 30 hours. Provides once-daily dosing with steady-state achieved after 7 days.
Fecal excretion is the primary route (approximately 68%), with renal excretion accounting for about 27% (mostly as metabolites).
Renal: ~60% as unchanged drug; Fecal: ~40% as metabolites and unchanged drug.
Category C
Category C
Oral Contraceptive
Oral Contraceptive